(IMRX) Immuneering - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45254E1073
Stock: Oncology Drugs, Cancer Treatments, Clinical Trials
Total Rating 47
Risk 83
Buy Signal 1.77
| Risk 5d forecast | |
|---|---|
| Volatility | 122% |
| Relative Tail Risk | -22.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.63 |
| Alpha | 235.15 |
| Character TTM | |
|---|---|
| Beta | 2.095 |
| Beta Downside | 1.040 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.29% |
| CAGR/Max DD | -0.12 |
Description: IMRX Immuneering March 05, 2026
Immuneering Corporation (IMRX) is a clinical-stage oncology company developing cancer treatments. The companys pipeline includes two lead product candidates, IMM-1-104 and IMM-6-415, both in Phase 1/2a clinical trials.
IMM-1-104 is a dual-MEK inhibitor targeting pancreatic, melanoma, and non-small cell lung cancers linked to RAS and/or RAF mutations. IMM-6-415 is also in Phase 1/2a for solid tumors. The biotechnology sector is characterized by high research and development costs and lengthy drug development timelines.
Founded in 2008 and based in Cambridge, Massachusetts, Immuneering focuses on oncology, a therapeutic area with significant unmet medical needs. Further research on platforms like ValueRay can provide deeper insights into IMRXs clinical trial progress and market potential.
Headlines to watch out for
- IMM-1-104 clinical trial results impact stock
- IMM-6-415 trial progress affects valuation
- Future drug approvals drive revenue potential
- Research and development costs weigh on profitability
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA 84.89 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.20 > 3% & CFO -45.3m > Net Income -56.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.6m) vs 12m ago 108.0% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.38%; Δ -1.38% > 0%) |
| Interest Coverage Ratio: -17.66 > 6 (EBITDA TTM -58.7m / Interest Expense TTM -3.36m) |
Altman Z'' -15.00
| A: 0.72 (Total Current Assets 176.2m - Total Current Liabilities 10.1m) / Total Assets 232.0m |
| B: -1.21 (Retained Earnings -280.3m / Total Assets 232.0m) |
| C: -0.42 (EBIT TTM -59.4m / Avg Total Assets 142.3m) |
| D: -20.75 (Book Value of Equity -280.2m / Total Liabilities 13.5m) |
| Altman-Z'' Score: -23.83 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 0.0/726.3k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.40 (AQ_t 0.22 / AQ_t-1 0.16) |
| SGI: none (Revenue 0.0 / 726.3k) |
| TATA: -0.05 (NI -56.0m - CFO -45.3m) / TA 232.0m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of IMRX shares?
As of March 10, 2026, the stock is trading at USD 5.62 with a total of 1,037,328 shares traded.
Over the past week, the price has changed by +12.40%, over one month by +13.54%, over three months by -9.94% and over the past year by +284.93%.
Over the past week, the price has changed by +12.40%, over one month by +13.54%, over three months by -9.94% and over the past year by +284.93%.
Is IMRX a buy, sell or hold?
Immuneering has received a consensus analysts rating of 4.20.
Therefore, it is recommended to buy IMRX.
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IMRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17 | 202.5% |
| Analysts Target Price | 17 | 202.5% |
IMRX Fundamental Data Overview March 10, 2026
P/S = 563.6155
P/B = 1.5096
Revenue TTM = 0.0 USD
EBIT TTM = -59.4m USD
EBITDA TTM = -58.7m USD
Long Term Debt = 3.43m USD (estimated: total debt 3.82m - short term 397.1k)
Short Term Debt = 397.1k USD (from shortTermDebt, last quarter)
Debt = 3.82m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 175.2m USD (344.2m + Debt 3.82m - CCE 172.8m)
Interest Coverage Ratio = -17.66 (Ebit TTM -59.4m / Interest Expense TTM -3.36m)
EV/FCF = -3.85x (Enterprise Value 175.2m / FCF TTM -45.5m)
FCF Yield = -25.97% (FCF TTM -45.5m / Enterprise Value 175.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 526.4k) / Revenue TTM)
Tobins Q-Ratio = 0.76 (Enterprise Value 175.2m / Total Assets 232.0m)
Interest Expense / Debt = 28.1k% (Interest Expense 1.08b / Debt 3.82m)
Taxrate = 21.0% (US default 21%)
NOPAT = -46.9m (EBIT -59.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.50 (Total Current Assets 176.2m / Total Current Liabilities 10.1m)
Debt / Equity = 0.02 (Debt 3.82m / totalStockholderEquity, last quarter 218.5m)
Debt / EBITDA = 2.13 (negative EBITDA) (Net Debt -124.8m / EBITDA -58.7m)
Debt / FCF = 2.74 (negative FCF - burning cash) (Net Debt -124.8m / FCF TTM -45.5m)
Total Stockholder Equity = 129.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.36% (Net Income -56.0m / Total Assets 232.0m)
RoE = -43.33% (Net Income TTM -56.0m / Total Stockholder Equity 129.3m)
RoCE = -44.74% (EBIT -59.4m / Capital Employed (Equity 129.3m + L.T.Debt 3.43m))
RoIC = -47.11% (negative operating profit) (NOPAT -46.9m / Invested Capital 99.6m)
WACC = 13.48% (E(344.2m)/V(348.0m) * Re(13.63%) + (debt cost/tax rate unavailable))
Discount Rate = 13.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 48.55%
[DCF] Fair Price = unknown (Cash Flow -45.5m)
EPS Correlation: -3.73 | EPS CAGR: 11.28% | SUE: 0.51 | # QB: 0
Revenue Correlation: -7.89 | Revenue CAGR: -0.05% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.31 | Chg7d=+0.048 | Chg30d=+0.053 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=-1.14 | Chg7d=+0.363 | Chg30d=+0.318 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-1.60 | Chg7d=+0.031 | Chg30d=-0.053 | Revisions Net=+2 | Growth EPS=-39.6% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Current Year)
P/B = 1.5096
Revenue TTM = 0.0 USD
EBIT TTM = -59.4m USD
EBITDA TTM = -58.7m USD
Long Term Debt = 3.43m USD (estimated: total debt 3.82m - short term 397.1k)
Short Term Debt = 397.1k USD (from shortTermDebt, last quarter)
Debt = 3.82m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 175.2m USD (344.2m + Debt 3.82m - CCE 172.8m)
Interest Coverage Ratio = -17.66 (Ebit TTM -59.4m / Interest Expense TTM -3.36m)
EV/FCF = -3.85x (Enterprise Value 175.2m / FCF TTM -45.5m)
FCF Yield = -25.97% (FCF TTM -45.5m / Enterprise Value 175.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 526.4k) / Revenue TTM)
Tobins Q-Ratio = 0.76 (Enterprise Value 175.2m / Total Assets 232.0m)
Interest Expense / Debt = 28.1k% (Interest Expense 1.08b / Debt 3.82m)
Taxrate = 21.0% (US default 21%)
NOPAT = -46.9m (EBIT -59.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.50 (Total Current Assets 176.2m / Total Current Liabilities 10.1m)
Debt / Equity = 0.02 (Debt 3.82m / totalStockholderEquity, last quarter 218.5m)
Debt / EBITDA = 2.13 (negative EBITDA) (Net Debt -124.8m / EBITDA -58.7m)
Debt / FCF = 2.74 (negative FCF - burning cash) (Net Debt -124.8m / FCF TTM -45.5m)
Total Stockholder Equity = 129.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.36% (Net Income -56.0m / Total Assets 232.0m)
RoE = -43.33% (Net Income TTM -56.0m / Total Stockholder Equity 129.3m)
RoCE = -44.74% (EBIT -59.4m / Capital Employed (Equity 129.3m + L.T.Debt 3.43m))
RoIC = -47.11% (negative operating profit) (NOPAT -46.9m / Invested Capital 99.6m)
WACC = 13.48% (E(344.2m)/V(348.0m) * Re(13.63%) + (debt cost/tax rate unavailable))
Discount Rate = 13.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 48.55%
[DCF] Fair Price = unknown (Cash Flow -45.5m)
EPS Correlation: -3.73 | EPS CAGR: 11.28% | SUE: 0.51 | # QB: 0
Revenue Correlation: -7.89 | Revenue CAGR: -0.05% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.31 | Chg7d=+0.048 | Chg30d=+0.053 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=-1.14 | Chg7d=+0.363 | Chg30d=+0.318 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-1.60 | Chg7d=+0.031 | Chg30d=-0.053 | Revisions Net=+2 | Growth EPS=-39.6% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Current Year)